Stockscreener 앱 받기
3.5479
1.99%
-0.0721
시간 외 거래:
3.53
-0.0179
-0.50%
전일 마감가:
$3.62
열려 있는:
$3.515
하루 거래량:
11,059
Relative Volume:
0.19
시가총액:
$2.61M
수익:
$4.79M
순이익/손실:
$-13.42M
주가수익비율:
-1.3338
EPS:
-2.66
순현금흐름:
$-10.30M
1주 성능:
-2.80%
1개월 성능:
-15.12%
6개월 성능:
-64.72%
1년 성능:
-85.52%
1일 변동 폭
$3.37
$3.63
1주일 범위
$3.37
$3.7491
52주 변동 폭
$2.96
$29.43
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
명칭
Qualigen Therapeutics Inc
전화
(760) 918-9165
주소
2042 CORTE DEL NOGAL, CALIFORNIA
QLGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
3.5479 | 2.61M | 4.79M | -13.42M | -10.30M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Qualigen Therapeutics Inc 주식(QLGN)의 최신 뉴스
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World
Qualigen to invest in NanoSynex, stock tumbles 21% - MSN
Qualigen Therapeutics Invests in NanoSynex’s Growth - TipRanks
Qualigen to participate in next funding round for NanoSynex - GlobeNewswire
This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics regains compliance with Nasdaq's listing requirements - MSN
Qualigen Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - Yahoo Finance
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - The Manila Times
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com
Qualigen Therapeutics secures $4.5 million in funding By Investing.com - Investing.com South Africa
Qualigen Therapeutics secures $4.5 million in funding - Investing.com India
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - The Manila Times
Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World
Qualigen Therapeutics Inc (QLGN) Quarterly 10-Q Report - Quartzy
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics appoints new board member By Investing.com - Investing.com Canada
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com Canada
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com India
Qualigen Therapeutics announces 1-for-50 reverse stock split By Investing.com - Investing.com UK
Qualigen Therapeutics (STU:7R90) Enterprise Value : €4.58 Mil (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Operating Cash Flow per Sh - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Shares Outstanding (EOP) : 0.19 Mil (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Long-Term Debt & Capital L - GuruFocus.com
Qualigen Therapeutics (STU:7R90) EV-to-Revenue : (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Cash Flow from Financing : €1.51 Mil (TTM As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Qualigen Therapeutics, Inc. Announces Appointment of Amy Broidrick as Executive Vice President and Chief Strategy Officer - Marketscreener.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Qualigen Therapeutics Stock to Reverse Split on Tuesday, November 5th (NASDAQ:QLGN) - Defense World
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Would I Buy Qualigen Therapeutics Inc (NASDAQ: QLGN) Stock At Any Time In The Future? - Stocks Register
Qualigen Therapeutics announces results of annual stockholder meeting By Investing.com - Investing.com Australia
Qualigen Therapeutics announces results of annual stockholder meeting - Investing.com India
Qualigen Therapeutics (STU:7R9) Enterprise Value : €4.47 Mil (As of Oct. 26, 2024) - GuruFocus.com
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - openPR
QLGN stock touches 52-week low at $0.11 amid market challenges - Investing.com India
Qualigen Therapeutics faces Nasdaq delisting notice By Investing.com - Investing.com Canada
Qualigen Therapeutics Inc (QLGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):